Imipenem E Cilastatina Sun (Cilastatin, Imipenem)

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, which blocks the cross‑linking of peptidoglycan strands and leads to cell lysis. Cilastatin, co‑formulated with imipenem, blocks renal dehydropeptidase I, preventing enzymatic degradation of imipenem and extending its antibacterial activity.

The dosage of Imipenem E Cilastatina Sun is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. Only a qualified healthcare professional should set the appropriate dosing regimen.

Safety data in pregnancy and lactation are limited. The drug should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians must evaluate each case individually and discuss potential risks with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Imipenem, combined with cilastatin, offers a broad spectrum of activity against Gram‑positive, Gram‑negative, and anaerobic bacteria, similar to other carbapenems like meropenem or ertapenem. Its unique cilastatin component protects it from renal degradation, allowing higher plasma concentrations, but clinical choice depends on pathogen susceptibility, dosing convenience, and patient-specific factors.

Store the product at room temperature, below 25 °C, in its original packaging. Keep it away from moisture and direct light. Do not freeze. Follow any additional handling instructions provided on the label to maintain product stability.

The medication is supplied for intravenous infusion. It is reconstituted with a suitable diluent and administered by a healthcare professional under aseptic conditions, typically over a prescribed period of time. Infusion rates and dilution volumes are determined by the prescriber based on the clinical scenario.

Serious adverse events include seizures (especially in patients with renal impairment or high doses), anaphylactic reactions, severe Clostridioides difficile‑associated colitis, nephrotoxicity, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Prompt medical attention is required if any of these occur.

Patients with a known hypersensitivity to imipenem, other carbapenems, or any component of the formulation should avoid this medication. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving valproic acid, unless the prescriber determines the benefits outweigh the risks.